Tuesday, December 13, 2022 12:02:38 PM
The dendritic cell is akin to a supercomputer when it interacts with the immune system (based upon millions of years of trial and error).
Improved and recently patented DCVax-Direct, for example, goes directly toward and into the tumor, and releases the correct cytokines to wage war upon cells that are cancerous. It also uptakes (nibbles) and even destroys cancer cells itself before leaving the tumor site to further mature and migrate to the lymph nodes**. It thereafter instructs matching t-cells to attack the cancer cells that do not belong.
With CSF1R additionally administered, cells that might normally temper/decrease an immune response are blocked from the scene, thus allowing a full blown immune response. By not utilizing chemo, killer/effector t-cells are not exhausted as easily and the duration of cancer cell death is extended.
Thereafter, unlike preselected antigens, each DCVax-Direct vaccination administration is akin to a new drug, because it picks up new or mutated antigens from cancer cells that might otherwise escape. This is the additional advantage over limited vaccines previously or currently in trial.
Unleash Dr. Bosch!!!
** Sometimes the dendritic cell can even find functioning lymph node sites within the tumor.
Improved and recently patented DCVax-Direct, for example, goes directly toward and into the tumor, and releases the correct cytokines to wage war upon cells that are cancerous. It also uptakes (nibbles) and even destroys cancer cells itself before leaving the tumor site to further mature and migrate to the lymph nodes**. It thereafter instructs matching t-cells to attack the cancer cells that do not belong.
With CSF1R additionally administered, cells that might normally temper/decrease an immune response are blocked from the scene, thus allowing a full blown immune response. By not utilizing chemo, killer/effector t-cells are not exhausted as easily and the duration of cancer cell death is extended.
Thereafter, unlike preselected antigens, each DCVax-Direct vaccination administration is akin to a new drug, because it picks up new or mutated antigens from cancer cells that might otherwise escape. This is the additional advantage over limited vaccines previously or currently in trial.
Unleash Dr. Bosch!!!
** Sometimes the dendritic cell can even find functioning lymph node sites within the tumor.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
